A Randomized, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI)
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Adomiparin (Primary) ; Heparin
- Indications Cardiovascular disorders; Coronary artery disease; Embolism and thrombosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms EMINENCE
- Sponsors Momenta Pharmaceuticals
- 07 Apr 2010 Results were published in Circulation, according to a Momenta Pharmaceuticals media release.
- 02 Oct 2009 Actual patient number (503) added as reported by ClinicalTrials.gov.
- 02 Oct 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.